BPC-157

What Is BPC-157?#

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (sequence: GEPPPGKPADDAGLV), derived from a protective protein naturally found in human gastric juice. With a molecular weight of approximately 1,419 Da and the CAS number 137525-51-0, BPC-157 has become one of the most extensively studied peptides in preclinical tissue repair research. This guide provides a comprehensive overview of BPC-157 peptide research, including its mechanism of action, therapeutic applications across body systems, regulatory status, and what the current evidence does and does not support. For detailed molecular properties, see the BPC-157 molecular structure page.

The peptide was originally identified and developed by researchers at the University of Zagreb, led by Predrag Sikiric, who isolated the parent protein from human gastric juice and systematically characterized its tissue-protective properties. The name "Body Protection Compound" reflects the peptide's origin from a gastrointestinal source and its broad cytoprotective effects observed across multiple organ systems in animal models. BPC-157 is also known by the pharmaceutical designation PL-14736 and has been referred to as Bepecin in some clinical contexts.

BPC-157 Mechanism of Action#

BPC-157 is a pleiotropic peptide with predominantly endothelial and cytoprotective actions. Rather than binding a single canonical receptor, BPC-157's effects converge on angiogenic signaling, nitric oxide (NO) modulation, cytoskeletal/migratory programs, and barrier stabilization. A broad receptor binding screen reported no direct pharmacological affinity for classical neurotransmitter receptor families, supporting an indirect or upstream modulatory mode of action.

VEGF-VEGFR2-Akt-eNOS Axis#

The primary signaling pathway through which BPC-157 promotes tissue healing involves vascular endothelial growth factor (VEGF) and its receptor system:

• VEGF/VEGFR upregulation: BPC-157 upregulates VEGF-A and VEGFR1/VEGFR2, rapidly inducing VEGFR2 phosphorylation with receptor internalization. The endocytosis inhibitor dynasore blocks these effects, indicating a requirement for VEGFR2 internalization.
• Downstream effectors: Activated VEGFR2 leads to AKT phosphorylation and eNOS activation. BPC-157 decreases eNOS-Caveolin-1 binding (releasing eNOS), consistent with increased NO bioactivity.
• Context dependence: In clopidogrel-impaired angiogenesis models, BPC-157 increased VEGF-A/VEGFR1 and AKT phosphorylation while inactivating p38/ERK MAPKs. NOS inhibition (L-NAME) abrogated AKT and p38 effects but not ERK, indicating partial NO-dependence.

Nitric Oxide System Modulation#

A distinctive feature of BPC-157 is its bidirectional normalization of the NO system:

• BPC-157 counteracts both NOS inhibition (e.g., L-NAME) and NOS overstimulation (e.g., L-arginine), normalizing tissue NO levels while suppressing free radical formation across ischemia/reperfusion and other injury models
• Effects include protection from thrombosis/arrhythmias and improved perfusion linked to collateral vessel recruitment
• The Src-Caveolin-1-eNOS signaling pathway is engaged to modulate vasomotor tone and collateral recruitment

Cell Migration and Tissue Repair Pathways#

BPC-157 activates focal adhesion kinase (FAK) and paxillin, promoting fibroblast outgrowth and migration. In tendon fibroblasts, BPC-157 upregulates growth hormone receptor (GHR) mRNA and protein, potentiating GH-induced JAK2 phosphorylation and increasing proliferation. This represents target-cell receptor sensitization rather than direct GH receptor agonism. Additionally, BPC-157 rapidly activates ERK1/2 with induction of early growth response gene egr-1 and its repressor nab2, supporting wound repair programs.

Platelet Function and Hemostasis#

BPC-157 improves thrombocyte function and reduces bleeding or thrombosis manifestations in vivo while standard coagulation parameters remain unaffected, implying modulation of platelet activation/adhesion or endothelial-platelet interactions rather than direct effects on the coagulation cascade.

BPC-157 Research by Body System#

Gastrointestinal Healing#

The gastrointestinal tract is the origin tissue for BPC-157 and the most extensively studied application:

• Colonic ischemia-reperfusion: Topical BPC-157 (10 mcg/kg) rapidly restored microvascular perfusion in rat models, reducing ischemic pale area from 86% to 10% within 15 minutes, with normalization of tissue malondialdehyde and NO levels
• Fistula healing: In rat colocutaneous fistula models, daily BPC-157 achieved complete fistula closure by day 28, outperforming sulphasalazine. In rectovaginal fistula models, all BPC-157-treated rats showed no fecal leakage versus persistent leakage in controls
• Intestinal anastomosis: Across multiple rat models, BPC-157 accelerated revascularization, recruited collaterals, preserved mucosa, and reduced adhesions
• Ulcerative colitis: A small multicenter RCT (n=53) using 80 mg BPC-157 enema daily for two weeks reported statistically significant decreases in Disease Activity Index versus placebo, though full results have not been posted publicly

Tendon and Ligament Repair#

BPC-157 has shown consistent effects on connective tissue healing in rodent models:

• After rat medial collateral ligament transection, BPC-157 restored biomechanical properties toward normal by day 14: breaking force ~34.1 N, elongation ~2.3 mm, absorbed energy ~34.8 N-mm, stiffness ~20.3 N/mm
• Macroscopic fiber organization normalized and inflammatory markers decreased
• In vitro, BPC-157 increased tendon fibroblast growth hormone receptor expression, supporting enhanced proliferation when combined with GH
• A 2025 systematic review of 36 studies (35 preclinical, 1 clinical) confirmed consistent improvement in functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bony injury models

Neurological and Spinal Cord Injury#

• In rat spinal cord compression, a single dose of BPC-157 (2 or 200 mcg/kg) 10 minutes post-injury produced consistent functional recovery: improved tail motor scores, resolved spasticity by day 15, and prevented autotomy
• Histology showed markedly fewer vacuoles and necrosis in white and gray matter
• BPC-157 counteracted cuprizone-induced brain demyelination and motor disability in rodent models
• Although behavioral and physiological data indicate normalization across dopaminergic, serotonergic, glutamatergic, GABAergic, cholinergic, and adrenergic systems, the absence of direct receptor binding suggests upstream vascular/cytoprotective mechanisms mediate these effects

Wound Healing and Skin#

• In rat alkali-burn models, topical BPC-157 (200-800 ng/mL) accelerated wound closure to 77-82% by day 18 versus 60% in controls, matching or approaching bFGF
• Histology showed superior granulation, re-epithelialization, collagen deposition, and increased VEGF-A expression
• In HUVECs, BPC-157 increased proliferation, migration, and tube formation via ERK1/2 signaling

Ocular Protection#

In rat glaucoma models, BPC-157 given as eye drops, intraperitoneally, or orally immediately normalized intraocular pressure, reversed mydriasis, and preserved retinal ganglion cells, optic nerve thickness, and fundus vessel appearance, both prophylactically and when started 24 hours post-injury.

Additional Applications#

• Stress urinary incontinence: BPC-157 restored leak-point pressure to near-healthy values in female rat models with higher desmin, SMA positivity, and increased CD34+ vessel density
• Analgesia: Short-lived antinociceptive effects observed in rat incisional and formalin pain models, with shorter duration than morphine

BPC-157 Oral vs Injectable Research#

A distinguishing feature of BPC-157 compared to most research peptides is its reported stability in gastric acid, consistent with its origin from a gastric juice protein. Both oral and injectable (subcutaneous, intraperitoneal) administration routes have shown efficacy in animal studies:

• Oral administration: BPC-157 is consistently described as stable in human gastric juice and freely soluble in water at pH 7.0. Animal studies have used oral doses (typically 10 mcg/kg in drinking water at 0.16 mcg/mL) with reported therapeutic effects across GI, musculoskeletal, and other models. However, human Phase 1 data showed no quantifiable BPC-157 in plasma or urine after oral dosing, raising significant questions about systemic bioavailability.
• Injectable administration: Subcutaneous and intraperitoneal routes have been the most common in animal studies, with doses typically ranging from 10 ng/kg to 10 mcg/kg. Local injection (intra-articular, perilesional) has also been studied.
• Key uncertainty: The discrepancy between robust oral efficacy in animal studies and undetectable systemic levels in humans remains unexplained. Possible explanations include local GI effects without systemic absorption, species differences in peptide absorption, or assay sensitivity limitations.

BPC-157 Regulatory Status (2026 Update)#

BPC-157's regulatory history has been dynamic:

• Pre-2023: BPC-157 was available as a research chemical and through compounding pharmacies with physician prescription
• Late 2023: The FDA reclassified BPC-157 and 18 other peptides as "Category 2" bulk drug substances, citing concerns about immunogenicity, manufacturing impurities, and lack of large-scale human clinical trial data. This effectively banned compounding pharmacies from preparing these peptides
• February 27, 2026: HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides, including BPC-157, would be reclassified from Category 2 back to Category 1, allowing licensed compounding pharmacies to prepare them with a physician prescription

BPC-157 remains unapproved by the FDA for any specific medical indication. It has not completed Phase 2 or Phase 3 clinical trials. The reclassification allows compounding access but does not constitute FDA approval of safety or efficacy.

BPC-157 is not currently on the World Anti-Doping Agency (WADA) prohibited list, though this status has been described as evolving, and athletes should verify current regulations before use.

BPC-157 Clinical Evidence and Safety#

Human Studies#

The human evidence base for BPC-157 remains limited:

• Phase 1 oral safety/PK (NCT02637284): 42 healthy volunteers received oral BPC-157 at 1-9 mg/day for up to two weeks. Reported as safe and well tolerated, but with no quantifiable BPC-157 detected in plasma or urine. No posted results identified in clinical trial registries.
• Phase 1 rectal PK: 32 healthy males in a single-blind, placebo-controlled rectal dosing study. Good tolerability with most plasma concentrations below the assay's lower limit of quantification.
• Ulcerative colitis RCT: Multicenter, randomized, double-blind, placebo-controlled trial (n=53) using 80 mg enema daily for two weeks. Reported significant decrease in Disease Activity Index. No registry identifier or posted full results found.
• Small clinical series: Uncontrolled reports include intra-articular injections for knee pain (n=16) and interstitial cystitis (n=12), with subjective improvement but no controls.

Safety Profile#

• Animal toxicology summaries claim high acute tolerability (LD50 not reached at high doses)
• No serious adverse effects reported at standard research doses in animal studies
• Human safety assertions rely on small early-phase studies and anecdotal reports without systematic pharmacovigilance
• Standard coagulation parameters remain unaffected despite platelet function modulation

BPC-157 Evidence Gaps and Limitations#

The current evidence base for BPC-157 has important limitations that should inform interpretation:

• Concentration of authorship: Many preclinical findings originate from overlapping research groups, with limited independent replication
• No completed Phase 2/3 trials: Human efficacy remains unconfirmed by robust, publicly posted randomized trials
• Uncertain pharmacokinetics: Human studies frequently report plasma levels below quantification limits after oral and rectal dosing
• Publication venue concerns: Several comprehensive reviews and primary reports appear in lower-quality journals
• Methodological variability: Small sample sizes, inconsistent endpoints, and limited adverse-event reporting across preclinical studies
• Translation uncertainty: Extensive rodent evidence may not directly translate to human clinical outcomes

Key Research Findings#

Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in human tendon fibroblasts, published in Molecules (Chang CH et al., 2014; PMID: 25415472):

• Increased GH receptor expression in tendon fibroblasts
• Enhanced cell migration
• Promoted tendon healing markers

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon anastomosis and counteracts cuprizone brain injuries and motor disability, published in Journal of Physiology and Pharmacology (Sikiric P et al., 2013; PMID: 24304574):

• Improved colitis healing
• Enhanced anastomosis healing
• Reduced neurological damage markers

Pentadecapeptide BPC 157 reduces bleeding time and thrombocytopenia after amputation in rats treated with heparin, warfarin or aspirin, published in Blood Coagulation & Fibrinolysis (Stupnisek M et al., 2015; PMID: 25897838):

• Reduced bleeding time
• Improved platelet function
• Potential hemostatic effects

Related Reading#

• BPC-157 molecular structure and properties
• BPC-157 research studies and evidence
• BPC-157 dosing protocols
• BPC-157 side effects profile
• BPC-157 risks and safety considerations
• Similar peptides to BPC-157
• TB-500 research guide -- Thymosin beta-4 fragment for tissue repair
• GHK-Cu research guide -- Copper peptide for wound healing
• Alprostadil research guide -- Prostaglandin for vascular healing
• ARA-290 research guide -- Cytoprotective peptide